Table 7

Follow-up therapy according to best overall response (BOR) (complete response (CR), stable disease (SD), Partial response (PR) and progressive disease (PD)) and first and second line therapy with talimogene laherparepvec (T-VEC)

Follow-up therapy according to BOR and first and second line therapy with T-VEC
Patients with follow-up therapyBRAF MEK inhibitorPD-1
Inhibitor
PD-1+CTLA4 InhibitorCTLA4
Inhibitor
Chemo- therapyElectro-chemotherapy
First line therapy14/45 (15.9%)1 (1.1%)10 (11.4%)1 (1.1%)2 (2.3%)
with T-VEC
Second line therapy19/43 (21.6%)7 (8.0%)6 (6.8%)3 (3.4%)2 (2.3%)1 (1.1%)
with T-VEC
In total33/88 (37.5%)8 (9.1%)16 (18.2%)4 (4.5%)2 (2.3%)1 (1.1%)2 (2.3%)
BOR
CR6/38 (6.8%)1 (1.1%)4 (4.5%)1 (1.1%)
SD3/8 (3.4%)1 (1.1%)1 (1.1%)1 (1.1.%)
PR6/18 (6.8%)3 (3.4%)2 (2.3%)1 (1.1%)
PD18/24 (20.4%)3 (3.4%)9 (10.2%)2 (2.3%)2 (2.3%)1 (1.1%)1 (1.1%)
In total33/88 (37.5%)8 (9.1%)16 (18.2%)4 (4.5%)2 (2.3%)1 (1.1%)2 (2.3%)